Pub Date : 2025-10-21DOI: 10.1038/s41408-025-01373-y
Nicholas J Short,Elias Jabbour,Walid Macaron,Nitin Jain,Fadi G Haddad,Sanam Loghavi,Tapan M Kadia,Partow Kebriaei,Eitan Kugler,Jairo Matthews,Rebecca Garris,Farhad Ravandi,Hagop Kantarjian
Baseline cytomolecular features and measurable residual disease (MRD) dynamics are both strongly prognostic in acute lymphoblastic leukemia (ALL). Whether early MRD response can overcome the adverse prognosis of high-risk (HR) cytomolecular features is largely unknown. We retrospectively identified 161 patients with newly diagnosed B-cell ALL who underwent MRD assessment with next-generation sequencing (NGS) for IG/TR rearrangements (sensitivity: 1 × 10-6). Early NGS MRD negativity (i.e. after 1 cycle of induction) was achieved in 33% of patients. Rates of NGS MRD negativity were similar in patients with standard-risk (SR) and HR cytomolecular features. Patients who achieved early NGS MRD negativity had the best outcomes (2-year relapse-free survival (RFS): 94% versus 66% if MRD-positive; P = 0.03). None of the 26 patients with early NGS MRD negativity subsequently relapsed. Early NGS MRD response also identified patients with HR Philadelphia-chromosome (Ph)-negative ALL with low risk of relapse and excellent long-term survival (2-year RFS: 100%); in contrast, the 2-year RFS was 38% for patients with HR ALL who remained MRD-positive after induction (P = 0.01). Outcomes remained poor for HR patients who achieved NGS MRD negativity at later timepoints. In a landmark analysis, allogeneic stem cell transplant (alloSCT) improved outcomes of patients with HR Ph-negative ALL who remained MRD-positive after induction (2-year RFS 80% versus 0% if no alloSCT; P = 0.009). In patients with B-cell ALL, achievement of early NGS MRD negativity is associated with durable remissions, regardless of baseline cytomolecular features. AlloSCT may improve outcomes of patients with HR ALL with suboptimal early MRD dynamics.
{"title":"Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL.","authors":"Nicholas J Short,Elias Jabbour,Walid Macaron,Nitin Jain,Fadi G Haddad,Sanam Loghavi,Tapan M Kadia,Partow Kebriaei,Eitan Kugler,Jairo Matthews,Rebecca Garris,Farhad Ravandi,Hagop Kantarjian","doi":"10.1038/s41408-025-01373-y","DOIUrl":"https://doi.org/10.1038/s41408-025-01373-y","url":null,"abstract":"Baseline cytomolecular features and measurable residual disease (MRD) dynamics are both strongly prognostic in acute lymphoblastic leukemia (ALL). Whether early MRD response can overcome the adverse prognosis of high-risk (HR) cytomolecular features is largely unknown. We retrospectively identified 161 patients with newly diagnosed B-cell ALL who underwent MRD assessment with next-generation sequencing (NGS) for IG/TR rearrangements (sensitivity: 1 × 10-6). Early NGS MRD negativity (i.e. after 1 cycle of induction) was achieved in 33% of patients. Rates of NGS MRD negativity were similar in patients with standard-risk (SR) and HR cytomolecular features. Patients who achieved early NGS MRD negativity had the best outcomes (2-year relapse-free survival (RFS): 94% versus 66% if MRD-positive; P = 0.03). None of the 26 patients with early NGS MRD negativity subsequently relapsed. Early NGS MRD response also identified patients with HR Philadelphia-chromosome (Ph)-negative ALL with low risk of relapse and excellent long-term survival (2-year RFS: 100%); in contrast, the 2-year RFS was 38% for patients with HR ALL who remained MRD-positive after induction (P = 0.01). Outcomes remained poor for HR patients who achieved NGS MRD negativity at later timepoints. In a landmark analysis, allogeneic stem cell transplant (alloSCT) improved outcomes of patients with HR Ph-negative ALL who remained MRD-positive after induction (2-year RFS 80% versus 0% if no alloSCT; P = 0.009). In patients with B-cell ALL, achievement of early NGS MRD negativity is associated with durable remissions, regardless of baseline cytomolecular features. AlloSCT may improve outcomes of patients with HR ALL with suboptimal early MRD dynamics.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"12 1","pages":"169"},"PeriodicalIF":12.8,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145338610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-20DOI: 10.1038/s41408-025-01380-z
Jia Xiang Jin,Britta Besemer,Büsranur Yilmaz,Mathias Hänel,Roland Fenk,Uta Bertsch,Kaarina-Jiayuan Gu,Christine Hanoun,Igor W Blau,Christoph Mann,Christof Scheid,Roland Schroers,Ivana von Metzler,Manfred Hensel,Eva-Maria Klein,Martin Hoffmann,Christoph Lutz,Hendrik Riesenberg,Uwe M Martens,Christian S Michel,Christian Kunz,Evgenii Shumilov,Deniz Gezer,Tobias A W Holderried,Karolin Trautmann-Grill,Carsten Müller-Tidow,Katja C Weisel,Marc S Raab,Hans J Salwender,Hartmut Goldschmidt,Elias K Mai
{"title":"Prospective systematic classification of causes of death in the course of multiple myeloma.","authors":"Jia Xiang Jin,Britta Besemer,Büsranur Yilmaz,Mathias Hänel,Roland Fenk,Uta Bertsch,Kaarina-Jiayuan Gu,Christine Hanoun,Igor W Blau,Christoph Mann,Christof Scheid,Roland Schroers,Ivana von Metzler,Manfred Hensel,Eva-Maria Klein,Martin Hoffmann,Christoph Lutz,Hendrik Riesenberg,Uwe M Martens,Christian S Michel,Christian Kunz,Evgenii Shumilov,Deniz Gezer,Tobias A W Holderried,Karolin Trautmann-Grill,Carsten Müller-Tidow,Katja C Weisel,Marc S Raab,Hans J Salwender,Hartmut Goldschmidt,Elias K Mai","doi":"10.1038/s41408-025-01380-z","DOIUrl":"https://doi.org/10.1038/s41408-025-01380-z","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"72 1","pages":"167"},"PeriodicalIF":12.8,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145331687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-20DOI: 10.1038/s41408-025-01384-9
M Korenkov,J Liebaert,S Yousefian,S Schwartz,U M Demel,J Braune,M C Odabasi,L Herzberg,D Böckle,N C Görür,V V Landenberg-Roberg,S Bohl,E Tregel,S Hennig,C Franke,S Haas,U Keller,J Krönke,A Busse
Ciltacabtagene-autoleucel (cilta-cel) is a CAR-T cell therapy highly active in relapsed/refractory multiple myeloma but can induce severe immune-mediated toxicities. We describe two patients who developed chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel. Patient 1 presented with rapidly progressive gait ataxia, flaccid paraparesis, and oculomotor palsy 112 days post infusion; Patient 2 developed an analogous syndrome on day 19. In both patients, electromyography and nerve-conduction studies confirmed sensorimotor axonal-demyelinating neuropathy; brain MRI and CSF infection panels were unremarkable. CAR-T cells were detectable in blood and CSF, yet a predominance of CD8⁺ non-CAR-Tcells was observed. TCR-β sequencing revealed a hyper-expanded clone (~30% of all reads) in patient 1 versus a polyclonal repertoire in patient 2. High-dose dexamethasone plus intravenous immunoglobulin failed to improve neurologic symptoms and prompted T-cell-depleting cyclophosphamide, which lowered CAR- and non-CAR-T cells. Patient 1 died from respiratory failure, whereas patient 2 improved and could be discharged. These observations indicate that CIDP is a severe complication of cilta-cel therapy and may arise from bystander expansion of autoreactive CD8⁺ T-cells rather than direct CAR-T cell activity. Timely escalation to T-cell-depleting therapy may improve outcomes.
{"title":"Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy.","authors":"M Korenkov,J Liebaert,S Yousefian,S Schwartz,U M Demel,J Braune,M C Odabasi,L Herzberg,D Böckle,N C Görür,V V Landenberg-Roberg,S Bohl,E Tregel,S Hennig,C Franke,S Haas,U Keller,J Krönke,A Busse","doi":"10.1038/s41408-025-01384-9","DOIUrl":"https://doi.org/10.1038/s41408-025-01384-9","url":null,"abstract":"Ciltacabtagene-autoleucel (cilta-cel) is a CAR-T cell therapy highly active in relapsed/refractory multiple myeloma but can induce severe immune-mediated toxicities. We describe two patients who developed chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel. Patient 1 presented with rapidly progressive gait ataxia, flaccid paraparesis, and oculomotor palsy 112 days post infusion; Patient 2 developed an analogous syndrome on day 19. In both patients, electromyography and nerve-conduction studies confirmed sensorimotor axonal-demyelinating neuropathy; brain MRI and CSF infection panels were unremarkable. CAR-T cells were detectable in blood and CSF, yet a predominance of CD8⁺ non-CAR-Tcells was observed. TCR-β sequencing revealed a hyper-expanded clone (~30% of all reads) in patient 1 versus a polyclonal repertoire in patient 2. High-dose dexamethasone plus intravenous immunoglobulin failed to improve neurologic symptoms and prompted T-cell-depleting cyclophosphamide, which lowered CAR- and non-CAR-T cells. Patient 1 died from respiratory failure, whereas patient 2 improved and could be discharged. These observations indicate that CIDP is a severe complication of cilta-cel therapy and may arise from bystander expansion of autoreactive CD8⁺ T-cells rather than direct CAR-T cell activity. Timely escalation to T-cell-depleting therapy may improve outcomes.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"78 1","pages":"168"},"PeriodicalIF":12.8,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145332002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prognostic impact of organ involvement in aggressive adult T-cell leukemia/lymphoma: definition of risk organ and proposal of a prognostic index.","authors":"Koji Jimbo,Ayumu Ito,Hirona Ichimura,Junichi Kuroda,Shohei Andoh,Aki Sato,Kazuaki Yokoyama,Takahiro Fukuda,Kaoru Uchimaru,Yasuhito Nannya","doi":"10.1038/s41408-025-01367-w","DOIUrl":"https://doi.org/10.1038/s41408-025-01367-w","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"36 1","pages":"166"},"PeriodicalIF":12.8,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-16DOI: 10.1038/s41408-025-01364-z
Simonetta Viviani, Chiara Pavoni, Sally F Barrington, Luca Guerra, Heiko Schöder, Peter Johnson, Amy A Kirkwood, Deborah M Stephens, Jonathan W Friedberg, Stephane Chauvie, Michael V Knopp, Stefano Luminari, Daniel Molin, Paolo Corradini, Andrea Gallamini, Alessandro Rambaldi, Corrado Tarella
PET after 2 ABVD cycles (PET-2) is widely adopted to select patients with classical Hodgkin lymphoma (cHL), who might benefit from intensifying or de-escalating therapy. Prolonged progression-free survival (PFS) has been reported in PET-2 positive patients switched to escalated BEACOPP (eBEACOPP) or BEACOPP-14. Nevertheless, the subgroup of patients with a PET-2 scored 5 according to Deauville score (PET-2 DS5) are known to poorly benefit from treatment intensification. To elucidate PET-2 DS5 outcome along with possible predictive factors of response to intensification, a pooled analysis from three multicenter trials, GITIL/FIL HD0607, RATHL, and SWOG S0816, was conducted. PFS and overall survival (OS) were assessed after 41-month median follow-up, the prognostic value of clinical, laboratory, and PET parameters at diagnosis was evaluated. Among 2231 patients, 136 (6%) PET-2 DS5 patients were identified. Their 3-year PFS was 32% (95% CI, 25-42), while the 3-year OS was 82% (95% CI, 75-89). In multivariate analysis low lymphocyte (< 600/mm3) counts were adversely associated with PFS, whereas age ≥ 45 years and leukocytes cells count <15 × 103/μL were barely associated with short OS. The study confirms on a suitable cohort of PET-2 DS5 patients, that this high-risk cHL subgroup has an inadequate response to treatment intensification. Nevertheless, PET-2 DS5 patients may still have good outcome after subsequent salvage treatments with > 80% survival at 3 years, thus excluding a real disease refractoriness. Few distinct parameters may have specific prediction for PFS or OS.
{"title":"Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials.","authors":"Simonetta Viviani, Chiara Pavoni, Sally F Barrington, Luca Guerra, Heiko Schöder, Peter Johnson, Amy A Kirkwood, Deborah M Stephens, Jonathan W Friedberg, Stephane Chauvie, Michael V Knopp, Stefano Luminari, Daniel Molin, Paolo Corradini, Andrea Gallamini, Alessandro Rambaldi, Corrado Tarella","doi":"10.1038/s41408-025-01364-z","DOIUrl":"10.1038/s41408-025-01364-z","url":null,"abstract":"<p><p>PET after 2 ABVD cycles (PET-2) is widely adopted to select patients with classical Hodgkin lymphoma (cHL), who might benefit from intensifying or de-escalating therapy. Prolonged progression-free survival (PFS) has been reported in PET-2 positive patients switched to escalated BEACOPP (eBEACOPP) or BEACOPP-14. Nevertheless, the subgroup of patients with a PET-2 scored 5 according to Deauville score (PET-2 DS5) are known to poorly benefit from treatment intensification. To elucidate PET-2 DS5 outcome along with possible predictive factors of response to intensification, a pooled analysis from three multicenter trials, GITIL/FIL HD0607, RATHL, and SWOG S0816, was conducted. PFS and overall survival (OS) were assessed after 41-month median follow-up, the prognostic value of clinical, laboratory, and PET parameters at diagnosis was evaluated. Among 2231 patients, 136 (6%) PET-2 DS5 patients were identified. Their 3-year PFS was 32% (95% CI, 25-42), while the 3-year OS was 82% (95% CI, 75-89). In multivariate analysis low lymphocyte (< 600/mm<sup>3</sup>) counts were adversely associated with PFS, whereas age ≥ 45 years and leukocytes cells count <15 × 103/μL were barely associated with short OS. The study confirms on a suitable cohort of PET-2 DS5 patients, that this high-risk cHL subgroup has an inadequate response to treatment intensification. Nevertheless, PET-2 DS5 patients may still have good outcome after subsequent salvage treatments with > 80% survival at 3 years, thus excluding a real disease refractoriness. Few distinct parameters may have specific prediction for PFS or OS.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"15 1","pages":"165"},"PeriodicalIF":11.6,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12533113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145306833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-16DOI: 10.1038/s41408-025-01362-1
Samaneh Maleknia,Sanam Rezaei Benam,Greg Ahmann,Rafael Fonseca,Diane F Jelinek,Reza Shahbazi
Multiple myeloma (MM) is characterized by the clonal proliferation of plasma cells in the bone marrow. Although the precise molecular mechanisms differentiating men and women in MM are not fully understood, uncovering these differences is crucial for improving personalized therapeutic approaches. Here, we show sex-specific dysregulation of exosomal non-coding RNAs (ncRNAs) in MM. We conducted an in-depth analysis of dysregulated ncRNAs in male and female patients, as well as MM cell lines, revealing distinct expression signatures across multiple clinical contexts, including newly diagnosed, relapse, progression, Hyperdiploid, non-Hyperdiploid, and treatment exposure. Our findings highlight the pivotal roles of lncRNAs and miRNAs in MM pathogenesis, detecting alterations in enriched pathways that influence key biological processes such as cellular proliferation, apoptosis, and gene regulation. We established a panel of ncRNAs with distinct sex-specific expression patterns, significant effects on mRNA regulation, and involvement in MM-associated biological pathways. Our results demonstrate that exosomes provide enhanced analytical resolution for detecting non-coding RNAs, enabling more sensitive and precise identification of transcriptomic alterations. These results suggest that sex-specific dysregulation of ncRNAs may contribute to differences in MM progression and therapy response. Ultimately, this study underscores the importance of exosomal ncRNA profiling in designing sex-tailored therapeutic strategies targeting dysregulated ncRNAs, paving the way for personalized medicine in MM.
{"title":"Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression.","authors":"Samaneh Maleknia,Sanam Rezaei Benam,Greg Ahmann,Rafael Fonseca,Diane F Jelinek,Reza Shahbazi","doi":"10.1038/s41408-025-01362-1","DOIUrl":"https://doi.org/10.1038/s41408-025-01362-1","url":null,"abstract":"Multiple myeloma (MM) is characterized by the clonal proliferation of plasma cells in the bone marrow. Although the precise molecular mechanisms differentiating men and women in MM are not fully understood, uncovering these differences is crucial for improving personalized therapeutic approaches. Here, we show sex-specific dysregulation of exosomal non-coding RNAs (ncRNAs) in MM. We conducted an in-depth analysis of dysregulated ncRNAs in male and female patients, as well as MM cell lines, revealing distinct expression signatures across multiple clinical contexts, including newly diagnosed, relapse, progression, Hyperdiploid, non-Hyperdiploid, and treatment exposure. Our findings highlight the pivotal roles of lncRNAs and miRNAs in MM pathogenesis, detecting alterations in enriched pathways that influence key biological processes such as cellular proliferation, apoptosis, and gene regulation. We established a panel of ncRNAs with distinct sex-specific expression patterns, significant effects on mRNA regulation, and involvement in MM-associated biological pathways. Our results demonstrate that exosomes provide enhanced analytical resolution for detecting non-coding RNAs, enabling more sensitive and precise identification of transcriptomic alterations. These results suggest that sex-specific dysregulation of ncRNAs may contribute to differences in MM progression and therapy response. Ultimately, this study underscores the importance of exosomal ncRNA profiling in designing sex-tailored therapeutic strategies targeting dysregulated ncRNAs, paving the way for personalized medicine in MM.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"46 1","pages":"162"},"PeriodicalIF":12.8,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-16DOI: 10.1038/s41408-025-01375-w
Suheil Albert Atallah-Yunes,Thomas M Habermann,Matthew J Rees,Lay She Ng,Urshila Durani,Yucai Wang,Rebecca L King,Arushi Khurana
EBV-positive polymorphic B-cell lymphoproliferative disorder, NOS (poly B-LPD), is a newly defined entity in the 2022 International Consensus Classification of mature lymphoid neoplasms. Its clinical behavior and optimal treatment approach remain poorly characterized. We conducted a retrospective study of 31 patients diagnosed with EBV+ poly B-LPD at Mayo Clinic (2003-2024), excluding transplant recipients. Median age was 56 years; 71% had extranodal involvement, 68% presented with stage III/IV disease, and 52% had autoimmune conditions. Thirty-five percent (n = 11) were on immunosuppressive therapy at diagnosis, all of whom underwent reduction of immunosuppression (RIS); five underwent RIS alone, achieving four complete responses including two with central nervous system (CNS) involvement. Rituximab was effective in patients with or without prior immunosuppression. Histologic transformation to diffuse large B-cell lymphoma (DLBCL) or emergence of T-cell lymphomas occurred in immunochemotherapy non-responders or at relapse, emphasizing the role of re-biopsy in this subset of patients. At a median follow-up of 6 years, median event-free (EFS) and overall survival (OS) were 8.5 and 8.7 years, respectively. EFS was not significantly influenced by increasing IPI scores (p = 0.09), CNS involvement (p = 0.5), or immunosuppression at diagnosis (p = 0.2). There was a trend towards improved OS in patients who were on immunosuppressive therapy at diagnosis, however, this was not statistically significant, p = 0.054. This is the first study to characterize EBV+ poly B-LPD within the ICC 2022 framework. Larger studies are needed to validate these findings, define prognostic markers and guide therapy.
{"title":"EBV+ polymorphic B-cell lymphoproliferative disorder, NOS: a single-center study of a newly recognized pathologic entity.","authors":"Suheil Albert Atallah-Yunes,Thomas M Habermann,Matthew J Rees,Lay She Ng,Urshila Durani,Yucai Wang,Rebecca L King,Arushi Khurana","doi":"10.1038/s41408-025-01375-w","DOIUrl":"https://doi.org/10.1038/s41408-025-01375-w","url":null,"abstract":"EBV-positive polymorphic B-cell lymphoproliferative disorder, NOS (poly B-LPD), is a newly defined entity in the 2022 International Consensus Classification of mature lymphoid neoplasms. Its clinical behavior and optimal treatment approach remain poorly characterized. We conducted a retrospective study of 31 patients diagnosed with EBV+ poly B-LPD at Mayo Clinic (2003-2024), excluding transplant recipients. Median age was 56 years; 71% had extranodal involvement, 68% presented with stage III/IV disease, and 52% had autoimmune conditions. Thirty-five percent (n = 11) were on immunosuppressive therapy at diagnosis, all of whom underwent reduction of immunosuppression (RIS); five underwent RIS alone, achieving four complete responses including two with central nervous system (CNS) involvement. Rituximab was effective in patients with or without prior immunosuppression. Histologic transformation to diffuse large B-cell lymphoma (DLBCL) or emergence of T-cell lymphomas occurred in immunochemotherapy non-responders or at relapse, emphasizing the role of re-biopsy in this subset of patients. At a median follow-up of 6 years, median event-free (EFS) and overall survival (OS) were 8.5 and 8.7 years, respectively. EFS was not significantly influenced by increasing IPI scores (p = 0.09), CNS involvement (p = 0.5), or immunosuppression at diagnosis (p = 0.2). There was a trend towards improved OS in patients who were on immunosuppressive therapy at diagnosis, however, this was not statistically significant, p = 0.054. This is the first study to characterize EBV+ poly B-LPD within the ICC 2022 framework. Larger studies are needed to validate these findings, define prognostic markers and guide therapy.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"119 1","pages":"163"},"PeriodicalIF":12.8,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-16DOI: 10.1038/s41408-025-01379-6
David E Mery,Guido Tricot,Samer Al Hadidi,Yihao Zhan,Cody Ashby,Clyde Bailey,Eric R Siegel,Daisy V Alapat,Hongwei Xu,Sandra Mattox,Caroline Schinke,Maurizio Zangari,Sharmilan Thanendrarajan,Qing Yi,Robert Z Orlowski,Frits van Rhee,John D Shaughnessy,Fenghuang Zhan
{"title":"Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans.","authors":"David E Mery,Guido Tricot,Samer Al Hadidi,Yihao Zhan,Cody Ashby,Clyde Bailey,Eric R Siegel,Daisy V Alapat,Hongwei Xu,Sandra Mattox,Caroline Schinke,Maurizio Zangari,Sharmilan Thanendrarajan,Qing Yi,Robert Z Orlowski,Frits van Rhee,John D Shaughnessy,Fenghuang Zhan","doi":"10.1038/s41408-025-01379-6","DOIUrl":"https://doi.org/10.1038/s41408-025-01379-6","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"46 1","pages":"164"},"PeriodicalIF":12.8,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-13DOI: 10.1038/s41408-025-01383-w
Tara Sebastian, Sridevi Rajeeve, Tasmin Farzana, Ross Firestone, Eric Jurgens, Kevin Miller, Bruno Almeida Costa, Alexander Lesokhin, Carlyn Rose Tan, Gunjan Shah, Neha Korde, Heather Landau, Michael Scordo, Hani Hassoun, Kylee Maclachlan, Urvi Shah, Malin Hultcrantz, Andriy Derkach, Derkach Nemirovsky, Sergio Giralt, Saad Usmani, Sham Mailankody, Hamza Hashmi
{"title":"Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.","authors":"Tara Sebastian, Sridevi Rajeeve, Tasmin Farzana, Ross Firestone, Eric Jurgens, Kevin Miller, Bruno Almeida Costa, Alexander Lesokhin, Carlyn Rose Tan, Gunjan Shah, Neha Korde, Heather Landau, Michael Scordo, Hani Hassoun, Kylee Maclachlan, Urvi Shah, Malin Hultcrantz, Andriy Derkach, Derkach Nemirovsky, Sergio Giralt, Saad Usmani, Sham Mailankody, Hamza Hashmi","doi":"10.1038/s41408-025-01383-w","DOIUrl":"10.1038/s41408-025-01383-w","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"15 1","pages":"161"},"PeriodicalIF":11.6,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12518869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：